Wells Fargo Starts Rigel Pharmaceuticals (RIGL) at Outperform; Growing Enthusiasm For New Oral RA Therapies
Tweet Send to a Friend
Wells Fargo initiates coverage on Rigel Pharmaceuticals (NASDAQ: RIGL) with a Outperform. $10-12 Valuation Range.
Wells analyst says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Wells analyst says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
